German biotech firm Tacalyx snags seed funding

Berlin-based Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA cancer therapies, has secured 7 million euros in seed funding. Boehringer Ingelheim Venture Fund and Kurma Partners led the round with participation from Idinvest Partners, High-Tech Gründerfonds, coparion and Creathor Ventures.

Source: Press Release